Index

Page numbers in *italics* refer to illustrations; those in **bold** refer to tables

- acoustic radiation force imaging (ARFI) 118, 125, 128
- adenosine monophosphatase-activated protein kinase (AMPK) 53–54
- adiponectin 52, 66, 107, 224
  - agonist therapy 224
- adiponutrin 98
  - *see also* PNPLA3 gene polymorphism
- adipose tissue 66
  - inflammation 83, 84
- adipose triglyceride lipase (ATGL) 98
- Africa, prevalence studies 10
- alanine aminotransferase (ALT) 104, 105
  - AST/ALT ratio 127
  - screening application 164–166
- alcoholic foamy degeneration 74
- alcoholic liver disease (ALD) 72
  - grading and staging 79
- NAFLD comparison 73, 78
  - differentiation 73
  - fibrosis 76–77
  - hepatocellular injury 75–76
  - inflammation 75
  - steatosis 72–75
- alcoholic steatohepatitis (ASH) 5
- American Association for the Study of Liver Diseases (AASLD)
  - guidelines 131
  - NAFLD definition 131
  - NAFLD/NASH distinction 132–133
  - paediatric patients 134
  - screening 132, 162
  - therapy 133, 134
- American Board of Obesity Medicine (ABOM) 173
- anti-LOXL2 monoclonal antibody 224
- anti-LPS hyperimmune bovine colostrum (Imm124-E) 225
- antifibrotic therapies 220
  - clinical trial design challenges 221–222
  - knowledge of disease natural history 221
  - non-invasive monitoring 221–222
  - patient selection 221
  - trial end points 222
  - emerging therapies 222–225
  - targets 220, 221
  - *see also* fibrosis
- antilipolytic insulin sensitivity measurement 20–21
- antioxidant therapy 185–186, 216
  - *see also* oxidative stress
- apoptosis 62, 76
- APRI score 127
- aramchol 215
- Asia, prevalence studies 9–10
- aspartate aminotransferase (AST) 105
  - AST/ALT ratio 127
  - screening application 164
- atorvastatin 216
- Australasia, prevalence studies 10
- autoimmune liver disease 32
  - cryptogenic cirrhosis relationship 40
  - BARD score 117, 127
- bariatric surgery 198–203, 203
  - benefits of 202
development of 198
glucose intolerance reduction 192
duodenal switch 200
gastric bypass 198, 199
guidelines 133
jejunoileal bypass 198
laparoscopic AGB 199–200
laparoscopic sleeve gastrectomy 200, 200
mini‐gastric bypass 201
patient management 178–179
risks of 201–202
acute complications 201
long-term complications 201–202
mortality 202
vertical banded gastroplasty 199
Barker's hypothesis 228
Belfiore insulin sensitivity index 21
bile acids 84, 215
biliary atresia 32
bilirubinostasis 77
Blx-1002 214
bone mineral density (BMD), bariatric surgery patients 179
both alcoholic and metabolic steatohepatitis (BASH) 5
British Society of Gastroenterology (BSG) guidelines 131
paediatric patients 134
therapy 133
burned-out NASH 115
caffeine 184
candidate gene studies 54, 92, 94–96
cannabinoid receptor blockade 192, 225
carbohydrate response element‐binding protein (ChREBP) 98
cardiovascular disease (CVD)
mechanistic link between NAFLD and CVD 104–108
ER stress 106–107
inflammation 105
insulin resistance role 105
lipid metabolism disturbance 104
oxidative stress 105–106
NAFLD association 104, 107
 genetic association 107–108
post-liver transplant cardiovascular events 206
CC chemokine receptor antagonists 225
cell death 62, 76
fibrogenic liver repair relationship 62–63, 63
chemical-associated steatohepatitis (CASH) 5
childhood NAFLD see paediatric NAFLD
choledocholithiasis 75
cholestasis 77–79
choline deficiency 86–87, 87
chromosome 19 locus 99–100
chromosome 22 locus 97–99
chronic kidney injury (CKI) 207
cirrhosis 4, 10
causes 37
cryptogenic 4, 36–37, 206
 definition 37
future directions 41
NAFLD/NASH as cause 37–40
other possible causes 40–41
hepatocellular cancer association 4
paediatric population 29, 30, 33
risk factors for progression 32–33
clinical trials
antifibrotic therapies 222, 223
trial design challenges 221–222
shortage of 134, 135
coffee consumption benefits 183
Colesevelam 215
computed tomography (CT) 116, 125
fatty liver appearance 140, 140, 141
screening 140–141
 advantages and limitations 141
controlled attenuation parameter (CAP) 116, 128, 154
cryptogenic cirrhosis see cirrhosis
Cushing's syndrome 176
cyclosporine 208
cysteamine 216
cytokeratin-18 (CK-18) fragments 117, 126
cytokines 25
 fibrogenesis regulation 63–64
damage-associated molecular patterns (DAMPs) 62–63
developmental programming 228–229
animal models 229
human studies 229
mechanisms 229–232, 231
epigenetic mechanism 230, 231
gut microbiota 230–232
immune mechanism 230
nervous system 230
diabetes 51
 bariatric surgery benefits 192
hepatocellular carcinoma association 51–52
liver transplantation outcome studies 206, 207–208
pharmaceuticals 192
screening implications 162–163
diacylglycerol acyltransferase (DGAT) 216
dietary management of obesity 177–178
weight loss effects on metabolic syndrome 191
dipeptidyl peptidase-4 (DPP-4) inhibition 192, 214
docosahexaenoic acid (DHA) 215
drug-associated steatohepatitis (DASH) 5
ductular reaction (DR) 62
paediatric population 31
duodenal switch 200
dysbiosis 65
see also intestinal microbiome

Edmonton Obesity Staging System 175, 176
eicosapentaenoic acid (EPA) 215
elastography 128, 222
magnetic resonance (MRE) 118, 125, 128
transient (TE) 117–118, 125, 128, 156, 167
elastometry 118
ELFO test 117, 125, 128, 133, 156
endogenous ethanol 87
dysbiosis 65
see also intestinal microbiome

Endogenous ethanol 87
endoplasmic reticulum (ER) stress 106–107
epigenetics 230
developmental programming mechanism 230, 231
hepatobiliary transport, endogenous 87
6α-ethyl-chenodeoxycholic acid see obeticholic acid (INT-747)
euglycaemic hyperinsulinaemic clamp 16–17, 18
Europe, prevalence studies 9
European Association for the Study of the Liver (EASL) guidelines 131
NAFLD definition 131–132
NAFLD/NASH distinction 132
screening 132, 162
therapy 133, 134
exenatide 224
extracellular matrix regulation 64
ezetimibe 193, 216
familial aggregation 92
see also genetic factors
familial combined hyperlipidaemia 20
farnesoid X receptor (FXR) 84, 215
farnesyl-diphosphate farnesyltransferase 1 (FDFT1) genotype 11
fasting-induced adipose factor (Fiaf) 83
fat mass and obesity-related protein (FTO) gene polymorphism 176
fatty acid mobilisation 23
free fatty acids (FFAs) 104
hepatic fatty acid uptake 24
fatty acid transport proteins (FATPs) 23, 24
fatty liver index (FLI) 116, 154, 164
fenofibrate 214
ferritin 127
FIB-4 score 117, 127
fibrobiotics 192–193, 214
fibroblast-specific protein (FSP) 31
FibroMeter™ 117, 125, 128, 133
FibroScan™ 118, 125, 128
fibrosis 5, 38–40, 61
alcoholic versus nonalcoholic liver disease 76–77
serum markers 117, 125, 127–128
fibrogenesis mechanisms 62–66
link between hepatocyte injury/death and repair 62–63, 63
local regulation 63–65, 64
non-liver factors 65–66, 65
following liver transplantation 206
lobular 77
molecular pathways 66–68
hedgehog signalling 66–67
osteopontin 67–68
TGF-β 68–69
paediatric population 29–32
perisinusoidal 38, 38
progression 38–40
monitoring 117
risk factors for 32–33
staging 115
liver biopsy 155–156
see also antifibrotic therapies
FibroTest™ 117, 125, 128, 133, 156
FLIP algorithm 114, 132
FoxO1 phosphorylation 21, 22
free fatty acids (FFAs) 104
galectin inhibitors 225
gamma-glutamyltranspeptidase (GGT) 105
gastric bypass 198, 199
laparoscopic 198
mini-gastric bypass 201
genetic factors 5, 11, 92–100
candidate gene studies 54, 92, 94–96
cardiovascular disease link with NAFLD 107–108
heritability evidence 91–92
familial aggregation 92
interethnic differences in susceptibility 92
metabolically normal NAFLD 45–46
obesity 176
see also PNPLA3 gene polymorphism; TM6SF2 gene polymorphism
genome-wide association studies (GWAS) 11, 92, 93
rapid fibrosis progression 32
GFT-505 214, 222–224
ghrelin 198
Index

- glitazones 134, 192
- glucagon-like peptide 1 (GLP-1) 214–215, 224
  - agonists 192, 214–215, 224
- glucokinase regulator (GCKR) 97
- gluconeogenesis regulation 21–22
- glycaemic control, bariatric surgery patients 178
- glycosyn thase kinase-3β (GSK3β) 107
- glycogenated nuclei 79
- growth hormone (GH) 66
- guidelines 131
  - NAFLD definition 131–132
  - NAFLD/NASH distinction 132–133
  - paediatric NAFLD 134
  - screening 132, 161–162
  - therapy 133–134
- gut flora see intestinal microbiome

- hedgehog (Hh) signalling 32, 63, 66–67
  - clinical relevance 67
  - modulation of 67
  - pathway components 66–67
  - summary of actions 67
- hemoglobin (Hb) concentrations 45
- Hepascore 128
- hepatic fatty acid uptake 24
- hepatic insulin resistance 24–25
- hepatic insulin resistance index 20
- hepatic progenitor cells (HPCs) 31
- hepatic steatosis index (HSI) 164
- hepatitis B virus (HBV)
  - comorbidity with NAFLD 11–12
  - cryptogenic cirrhosis relationship 40–41
  - prevalence 11–12
- hepatitis C virus (HCV) 36
  - comorbidity with NAFLD 12
  - cryptogenic cirrhosis relationship 40–41
  - paediatric population 32
  - prevalence 12
- hepatocellular carcinoma (HCC)
  - causes 50
  - cirrhosis association 4
  - diabetes association 51–52
  - genetic factor 54, 97–98
  - metabolic syndrome association 51–52
  - noncirrhotic HCC 51
  - obesity association 51
  - pathogenesis 52–54, 53
  - prevalence 10–11, 50
    - NAFLD association 10–11, 50
    - screening 50–51
    - treatment 50
- hepatocyte ballooning 5, 38–40, 38, 153
  - alcoholic versus nonalcoholic liver disease 75
  - diagnostic significance 114
  - herniation following gastric bariatric surgery 202
  - high-risk population 162–163
  - high-sensitivity C-reactive protein (CRP) 105, 177
  - histological findings 4–5, 38, 38, 114–115
  - homeostasis model assessment (HOMA) index 17–20
  - hypercortisolaemia 176
  - hyperinsulinaemia 23, 44
  - hypoxia 66
- idiopathic thrombocytopenia purpura (ITP) 4
- inflammation 38, 38, 64–65, 105, 153
  - adipose tissue 83, 84
  - alcoholic versus nonalcoholic liver disease 75
  - cardiovascular disease association 105
  - hepatocarcinogenesis promotion 86
  - intestinal microbiome relationship 65, 84–86
  - obesity-related 177
  - portal 115
  - proinflammatory state 86
- insulin actions 21
- insulin receptor substrate 1 (IRS1) 21, 22, 52
- insulin resistance (IR) 16, 105, 190
  - cardiovascular disease association 105
  - hepatic insulin resistance 24–25
  - intestinal microbiome relationship 83
  - measurement 16, 22
    - antilipolytic insulin sensitivity 20–21
    - euglycaemic hyperinsulinaemic clamp 16–17, 18
    - intravenous glucose tolerance test (IVGTT) 17, 19
    - surrogate measures 17–20
    - NAFLD relationships 15, 21–25, 24, 44
    - NAFLD treatment effects on 190–194
    - prevalence 8
    - screening implications 162–163
    - steatohepatitis and 25
    - see also metabolic syndrome
- insulin sensitivity 16
  - antilipolytic insulin sensitivity measurement 20–21
  - surrogate measures 17–20
  - see also insulin resistance (IR)
- insulin sensitizers 134, 186–187
- insulin therapy 192
- insulin tolerance test 20
- insulinoma 179
- INT-747 see obeticholic acid (INT-747)
- interleukin-6 (IL-6) 52
intestinal microbiome 54, 82–83
choline deficiency promotion 87, 87
developmental programming mechanism 230–232
endogenous ethanol production 87
inflammation relationship 65, 84–86
insulin resistance relationship 83
liver disease relationship 65–66, 224
NAFLD relationship 83–84
obesity relationship 83
therapeutic approaches 224
intravenous glucose tolerance test (IVGTT) 17, 19, 20–21
portal venous insulin levels 23, 23
iron overload 45, 46, 54
iron depletion therapy 47
Italian Association for the Study of the Liver (IASL) guidelines 131
NAFLD definition 131–132
NAFLD/NASH distinction 132–133
therapy 133, 134
JAK-STAT pathway 52
jejunoileal bypass 198
c-Jun amino-terminal kinases (JNKs) 53, 104
ketogenesis 25
Kleiner fibrosis stage 115
Kruppel-like factor 6 (KLF6) 97
Kupffer cells (KC) 230
laparoscopic AGB 199–200
laparoscopic gastric bypass 198
laparoscopic sleeve gastrectomy 200, 200
leptin 52, 66, 213–214
resistance 197
lifestyle interventions 47, 191
guidelines 133
lipid-lowering therapies 192–193
lipodystrophy 214
lipogenesis 23
lipopolysaccharide (LPS) 86
lipotoxicity 53
liraglutide 178, 215, 224
liver biopsy 10, 153, 157
contraindications 156–157
cost considerations 156
fibrosis staging 155–156
guidelines 132–133
hepatic comorbidity diagnosis 154
indications 119–120, 132–133, 167
management implications 157
NAFLD diagnosis 152–154
paediatric patients 134
patient safety 156
sample size and quality 156
steatohepatitis diagnosis 155
steatosis quantification 154
techniques 156
timing 120, 133
liver enzyme analysis 164–166
liver priming 30
liver repair 61, 62
deregulated repair 62
see also fibrosis
hormonal regulation 66
restorative repair 62
liver transplantation 10, 204–208
chronic kidney injury relationship 207
NAFLD recurrence 205–206
obesity impact 207
post-transplant cardiovascular events 206
results 205
LPS binding protein (LBP) 86
lysyl oxidase (LOX) L2 224
anti-LOXL2 monoclonal antibody 224
magnetic resonance elastography (MRE) 118, 125, 128
magnetic resonance imaging (MRI) 116, 125, 154
qualitative fat estimation 142–143
frequency-selected (FS) technique 142, 142
OIP technique 143, 143
quantitative fat estimation 144–145, 144
screening 141–145
magnetic resonance spectroscopy (MRS) 145–148, 146, 147, 154
malabsorption, bariatric surgery patients 179
Mallory–Denk bodies 38–40, 38, 74, 75
matrix metalloproteinases (MMPs) 64, 65
megamitochondria 75, 79
melanocortin receptor 4 gene mutation 176
metabolic physician 173
bariatric surgery patient management 178–179
definition 173–175
medical management of obesity 177–178
obese patient diagnosis and assessment 175–177
see also metabolic syndrome; obesity
metabolic risk factors 114
metabolic syndrome 8, 44, 190
as NAFLD risk factor 44–45
hepatocellular carcinoma association 51–52
liver transplantation outcome relationships 205–206
NAFLD treatment effects on 190–194
bariatric surgery 192
dietary weight loss 191
pharmacotherapies 192–194
prevalence 8, 11
screening implications 162
see also insulin resistance (IR); metabolic physician
metabolically normal NAFLD 45–48, 46
  genetic factors 45–46
  prognostic implications 46–47
  treatment approach 47
metadoxine 214
metformin 134, 192, 214
microbiota see intestinal microbiome
microRNAs (miRNAs) 54
mini-gastric bypass 201
mitochondriopathies 41

NAFLD see nonalcoholic fatty liver disease (NAFLD)
NAFLD activity score (NAS) 5, 115, 155
NAFLD fibrosis score (NFS) 117, 127
NAFLD index 164
NAFLD liver fat score 116
NashTest™ 126
necrosis 76
needle biopsy 156
see also liver biopsy
nesidioblastosis 179
neurocan (NCAN) 99
nicotinic acid 193
non-esterified fatty acid (NEFA) 23
antilipolytic insulin sensitivity evaluation 20, 21
nonalcoholic fatty liver disease (NAFLD) 3–4
  alcoholic liver disease comparison 73, 77
  differentiation 73
  see also alcoholic liver disease (ALD)
cardiovascular disease association 104, 107
  genetic association 107–108
  mechanistic link 104–108
comorbidity 11–12
  definition 131–132
diagnosis 113–114, 152–154
  hepatic comorbidity 154
  histological 115
  scoring systems 115–116
see also screening
disease severity 10–11
grading and staging 79
heritable component 91–92
see also genetic factors
high-risk population 162–163
insulin resistance relationships 15, 21–25, 24, 44
intestinal microbiome relationship 83–84
liver transplantation relationship 10
  disease recurrence following transplantation 205–206
loss of steatosis in late disease 40
  possible causes 40
metabolic syndrome relationships 44–45
pathogenesis related to hepatocellular carcinoma 52–54, 53
prevalence 8–12, 91, 103–104
  worldwide studies 9–10, 9
primary 114
risk factors 164
  identification of 166
  scoring systems 167
secondary 114
  causes 114
see also metabolically normal NAFLD; paediatric NAFLD
nonalcoholic steatohepatitis (NASH) 3–4, 36
burned-out NASH 115
cryptogenic cirrhosis relationship 37–40
diagnosis 113–114
  diagnostic criteria 38
  histological 114–115
  liver biopsy 155
  noninvasive diagnostic procedures 116–119, 126, 126
  recommendations 118–119, 119
hepatocellular carcinoma association 10–11, 50
high-risk population 162–163
histological features 38, 38
insulin resistance relationship 25
loss of steatosis in late disease 40
oxidative stress role 106
screening 167–168
simple steatosis distinction 113
noninvasive fibrosis tests (NILTs) 124–126
norepinephrine 66
nuclear erythroid 2-related factor (Nrf2) 216
nuclear factor-κβ (NF-κβ) 52
obesity 173, 197
  diagnosis and assessment 175–177
  dietary management 177–178
  weight loss effects on metabolic syndrome 191
  genetic factors 197
  syndromes 174
hepatocellular carcinoma association 51
heritability 176
intestinal microbiome relationship 83
liver transplantation outcome relationship 207
medical management 177–178, 192
NAFLD relationship 162, 163
prevalence 8, 11, 173, 197
related disease spectrum 174
screening implications 162–163
see also bariatric surgery
obstructive sleep apnea (OSA) 66
omega-3 polyunsaturated fatty acids 133, 193, 215
oral glucose insulin sensitivity (OGIS) index 20
oral glucose tolerance test (OGTT) 17, 21
orlistat 178, 184–185, 192
osteopontin (OPN) 67–68
clinical relevance 68
summary of actions 68
oxidative stress 106–107, 106, 185–186, 216
paediatric NAFLD 29–33
developmental origins 30
distinct pattern of disease 30–31
guidelines 134
histological evidence of early progression 30
long-term outcome 29
maternal BMI as predictor 30
pancreatitis 75
pentoxifylline 185, 193, 216
peptide YY 198
peroxisome proliferator-activated receptors (PPARs) 214
agonists 214, 222–224
phlebotomy 47
phosphatase and tensin homolog (PTEN) 52
phosphatidylethanolamine N-methyltransferase (PEMT) 97
Pima Indian studies 23
pioglitazone 134, 186, 192
pifendione 68
PNPLA3 gene polymorphism 5, 41, 97–99
fibrosis association 97
severity relationship 32
hepatocellular carcinoma association 54, 97–98
metabolically normal NAFLD 45, 46
NASH relationships 11, 97
product biological functions 98–99
polycystic ovary syndrome 176
polyphenols 184
portal hypertension 4
portal venous insulin levels 23, 23
post-prandial hypoglycaemia (PPH) 179
prevalence 8–12, 91, 103–104
disease severity 10–11
hepatitis B 11–12
hepatitis C 12
hepatocellular carcinoma 10–11, 50
metabolic syndrome 8, 11
obesity 8, 11, 173, 197
worldwide studies 9–10, 9
priming of the liver 30
probio benefits 86, 194, 224
procollagen III terminal peptide (PIIINP) 126
prolonged QTc interval 206
quantitative insulin sensitivity check index (QUICKI) 20
real-time shear wave elastography 118
reversed lobulation 39
rosiglitazone 186, 192
SAF score 115, 132, 155
scar tissue deposition 61
see also fibrosis
sclerosing hyaline necrosis 76
screening 161, 162
guidelines 132, 161–162
hepatocellular carcinoma (HCC) 50–51
high-risk population 162–163
methods 163–166, 165
computed tomography (CT) 140–141
liver enzyme analysis 164–166
magnetic resonance imaging (MRI) 141–145
magnetic resonance spectroscopy (MRS) 145–148
ultrasonography 138–140, 166, 167
NASH 167–168
practical approach 166–168, 167
risk factor identification 166
scoring systems 167
selective PPAR modulators (SPPARM) 214
serum markers 117, 125, 127–128
direct 125
indirect 125
short-chain fatty acids (SCFAs) 83
silymarin 216
sirolimus 208
sleeve gastrectomy 200, 200
small intestinal bacterial overgrowth (SIBO) 83–84, 85
SREBP-1c pathway 21–23
statins 193, 216
steatohepatitis see alcoholic steatohepatitis (ASH); nonalcoholic steatohepatitis (NASH)
steatosis 4, 24, 38, 72–75, 113, 152–153
alcoholic versus nonalcoholic liver disease 72–75
macroversicular steatosis 72–74
microvesicular steatosis 74–75
choline deficiency and 86–87
diagnosis 116
distinction from NASH 113
quantification 154–155
see also alcoholic steatohepatitis (ASH); nonalcoholic steatohepatitis (NASH)
SteatoTest 116
superoxide dismutase 2 (SOD2) 97
supersonic shear imaging (SSI) 125, 128
tacrolimus 208
TGR5 receptor 215
thiamine deficiency 179
thiazolidinediones (TZDs) 186, 214
side effects 186–187
thyroid disease 176
tissue inhibitors of metalloproteinases (TIMPs) 64
tissue repair 61, 62
deregulated repair 62
see also fibrosis
restorative repair 62
TM6SF2 gene polymorphism 5, 99–100
product biological function 99–100, 100
Toll-like receptors (TLRs) 105, 230
activation 54, 65, 86
transforming growth factor-beta (TGF-β) 63–64, 67, 68–69
clinical relevance 68–69
overexpression 68
transient elastography 117–118, 125, 128, 156, 167
triglyceride (TG) accumulation 104
tumor necrosis factor-α (TNF-α) 52, 185
ultrasonography 116, 118, 125, 154
fatty liver appearance 138–139, 139
screening 138–140, 166, 167
advantages and limitations 139–140
unfolded protein response (UPR) 106
United States, prevalence 9
ursodeoxycholic acid (UDCA) 134, 215
vertical banded gastroplasty 199
very-low-density lipoprotein (VLDL)
insulin-induced suppression 16, 44
overproduction 44
vitamin D 187
deficiency 178, 187
vitamin E 134, 185–186, 193, 216
side effects 186
volatile organic compounds (VOC) 86
VSL#3 224
Wernicke encephalopathy 179
Wilson disease 32
World Gastroenterology Organisation (WGO) guidelines 131
NAFLD definition 131
NAFLD/NASH distinction 133
screening 132
therapy 133, 134